Wells Fargo’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-142,783
| Closed | -$24.6M | – | 8274 |
|
|
2021
Q3 | $24.6M | Sell |
142,783
-42,032
| -23% | -$5.5M | 0.01% | 1509 |
|
|
2021
Q2 | $23.2M | Buy |
184,815
+59,120
| +47% | +$7.46M | 0.01% | 1569 |
|
|
2021
Q1 | $17M | Sell |
125,695
-12,618
| -9% | -$1.63M | ﹤0.01% | 1794 |
|
|
2020
Q4 | $17.7M | Buy |
138,313
+21,841
| +19% | +$2.56M | ﹤0.01% | 1643 |
|
|
2020
Q3 | $13.1M | Buy |
116,472
+56,826
| +95% | +$5.66M | ﹤0.01% | 1704 |
|
|
2020
Q2 | $5.68M | Buy |
59,646
+22,005
| +58% | +$2.12M | ﹤0.01% | 2351 |
|
|
2020
Q1 | $3.38M | Sell |
37,641
-10,428
| -22% | -$811K | ﹤0.01% | 2558 |
|
|
2019
Q4 | $2.55M | Buy |
48,069
+11,396
| +31% | +$520K | ﹤0.01% | 3149 |
|
|
2019
Q3 | $1.45M | Buy |
36,673
+3,083
| +9% | +$134K | ﹤0.01% | 3588 |
|
|
2019
Q2 | $1.38M | Sell |
33,590
-1,669
| -5% | -$69.1K | ﹤0.01% | 3648 |
|
|
2019
Q1 | $1.64M | Buy |
35,259
+1,524
| +5% | +$66.9K | ﹤0.01% | 3518 |
|
|
2018
Q4 | $1.47M | Sell |
33,735
-2,164
| -6% | -$108K | ﹤0.01% | 3536 |
|
|
2018
Q3 | $2.06M | Sell |
35,899
-102
| -0.3% | -$5.01K | ﹤0.01% | 3382 |
|
|
2018
Q2 | $1.75M | Buy |
36,001
+1,348
| +4% | +$49.1K | ﹤0.01% | 3559 |
|
|
2018
Q1 | $1.35M | Buy |
34,653
+1,287
| +4% | +$54.7K | ﹤0.01% | 3676 |
|
|
2017
Q4 | $1.42M | Sell |
33,366
-9,878
| -23% | -$370K | ﹤0.01% | 3660 |
|
|
2017
Q3 | $1.61M | Buy |
43,244
+5,247
| +14% | +$182K | ﹤0.01% | 3469 |
|
|
2017
Q2 | $1.15M | Sell |
37,997
-41,465
| -52% | -$1.2M | ﹤0.01% | 3636 |
|
|
2017
Q1 | $2.1M | Buy |
79,462
+40,910
| +106% | +$1.08M | ﹤0.01% | 3164 |
|
|
2016
Q4 | $983K | Buy |
38,552
+15,294
| +66% | +$485K | ﹤0.01% | 3705 |
|
|
2016
Q3 | $842K | Sell |
23,258
-225
| -1% | -$7.45K | ﹤0.01% | 3595 |
|
|
2016
Q2 | $798K | Sell |
23,483
-434
| -2% | -$14.1K | ﹤0.01% | 3634 |
|
|
2016
Q1 | $630K | Sell |
23,917
-347
| -1% | -$10.1K | ﹤0.01% | 3721 |
|
|
2015
Q4 | $1.18M | Buy |
24,264
+17,758
| +273% | +$639K | ﹤0.01% | 3372 |
|
|
2015
Q3 | $162K | Buy |
6,506
+266
| +4% | +$8K | ﹤0.01% | 4582 |
|
|
2015
Q2 | $198K | Buy |
6,240
+2,512
| +67% | +$81.1K | ﹤0.01% | 4617 |
|
|
2015
Q1 | $142K | Buy |
3,728
+2,036
| +120% | +$81K | ﹤0.01% | 4593 |
|
|
2014
Q4 | $66K | Buy |
1,692
+399
| +31% | +$13.9K | ﹤0.01% | 4918 |
|
|
2014
Q3 | $39K | Sell |
1,293
-513
| -28% | -$14.5K | ﹤0.01% | 5025 |
|
|
2014
Q2 | $62K | Buy |
1,806
+998
| +124% | +$33.4K | ﹤0.01% | 4885 |
|
|
2014
Q1 | $28K | Sell |
808
-796
| -50% | -$35.9K | ﹤0.01% | 5129 |
|
|
2013
Q4 | $64K | Buy |
+1,604
| New | +$38.7K | ﹤0.01% | 4678 |
|
Wells Fargo's XLRN Position: Q4 2021 in Review
Wells Fargo sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 142,783 shares — an estimated $24.6M sold.
Wells Fargo first reported a position in XLRN in Q4 2013 and held it in 32 quarters. The position peaked at $24.6M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Wells Fargo reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Wells Fargo sold 142,783 Acceleron Pharma shares in Q4 2021, an estimated $24.6M.
- Wells Fargo first reported a position in Acceleron Pharma in Q4 2013 and held it in 32 quarters.
- Wells Fargo's Acceleron Pharma position peaked at $24.6M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Wells Fargo's 13F filing for Q4 2021, filed 14 Feb 2022.